When shares of Optimer (NASDAQ: OPTR) jumped up in February on the news that it was seeking "strategic alternatives" -- in other words, looking for a buyer -- Motley Fool health-care analyst David Williamson warned that the company's defining drug, Dificid, has had slow sales, and finding a buyer might not be easy. However, in this video, David tells investors about an article in Bloomberg, reporting that both GlaxoSmithKline (GSK 2.20%) and AstraZeneca (AZN 2.59%) may be interested, which has shares of Optimer up 20%. David explores what Optimer has to offer that may or may not make this buyout worth the buyer's while.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Where did all this buyout interest come from?
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.